OVERVIEW OF ACTIVITY
Breast cancer remains the most frequently diagnosed cancer in women, and in 2013 in the United States alone the disease culminated in an estimated 232,340 new cases and 39,620 estimated deaths. Advances in screening and prevention have resulted in a steady down-stage migration at the time of disease presentation, such that only 5% of women have identifiable distant metastases at primary diagnosis. Because of this, the number of individuals living with breast cancer has increased substantially, as has the population “at risk” for recurrent disease.

TARGET AUDIENCE
This activity has been designed to meet the educational needs of medical oncologists, hematologist-oncologists, radiation oncologists, fellows and other healthcare providers involved in the treatment of lung cancer.

OVERVIEW OF ACTIVITY

OVERVIEW OF ACTIVITY

OVERVIEW OF ACTIVITY

RELEVANCE Trial Design

ECOG-E2408 Trial Design

OVERVIEW OF ACTIVITY

Each year, thousands of clinicians, basic scientists and other industry professionals sojourn to major international oncology conferences, like the American Society of Hematology (ASH) annual meeting, to hone their skills, network with colleagues and learn about recent advances altering state-of-the-art management in hematologic oncology. As such, these events have become global stages where exciting science, cutting-edge concepts and practice-changing data emerge on a truly grand scale. This massive outpouring of information has enormous benefits for the hematologic oncology community, but the truth is it also creates a major challenge for practicing oncologists and hematologists.